HLS Therapeutics (TSE:HLS) Shares Up 9.8%

Shares of HLS Therapeutics Inc. (TSE:HLS) rose 9.8% on Monday . The company traded as high as C$5.48 and last traded at C$5.04. Approximately 19,754 shares were traded during trading, an increase of 98% from the average daily volume of 9,985 shares. The stock had previously closed at C$4.59.

Wall Street Analysts Forecast Growth

HLS has been the topic of a number of recent research reports. Stifel Nicolaus dropped their price objective on HLS Therapeutics from C$4.35 to C$4.15 in a research report on Friday, March 15th. Raymond James lowered their price target on HLS Therapeutics from C$6.50 to C$5.00 in a report on Monday, March 18th. Finally, Clarus Securities reissued a “buy” rating on shares of HLS Therapeutics in a report on Tuesday, February 6th.

HLS Therapeutics Stock Performance

The company has a debt-to-equity ratio of 89.69, a current ratio of 1.65 and a quick ratio of 1.01. The firm has a market cap of C$160.88 million, a price-to-earnings ratio of -4.34 and a beta of 1.16. The firm has a fifty day simple moving average of C$4.10 and a two-hundred day simple moving average of C$4.19.

HLS Therapeutics (TSE:HLS) last issued its quarterly earnings results on Thursday, March 14th. The company reported C($0.18) earnings per share for the quarter, missing the consensus estimate of C($0.13) by C($0.05). The business had revenue of C$21.60 million during the quarter, compared to analyst estimates of C$21.83 million. HLS Therapeutics had a negative return on equity of 24.69% and a negative net margin of 43.65%. On average, analysts expect that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.